Trials / Completed
CompletedNCT05642312
A Study to Investigate Vamikibart in Participants With Uveitic Macular Edema
A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Investigate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Vamikibart Administered Intravitreally in Patients With Uveitic Macular Edema
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 245 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the efficacy and safety of vamikibart in participants with uveitic macular edema.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vamikibart | Participants will receive vamikibart IVT injection |
| OTHER | Sham | Participants will receive a sham procedure that mimics an IVT injection. |
Timeline
- Start date
- 2023-01-09
- Primary completion
- 2024-12-09
- Completion
- 2025-07-09
- First posted
- 2022-12-08
- Last updated
- 2025-11-21
Locations
77 sites across 14 countries: United States, Austria, Brazil, Canada, China, Israel, Italy, Mexico, Netherlands, Poland, Portugal, South Korea, Taiwan, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05642312. Inclusion in this directory is not an endorsement.